{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Approved OTC
Source:
21 CFR 333.120 first aid antibiotic:ointment polymyxin b sulfate (combination only)
Source URL:
First approved in 1951
Class:
MIXTURE
Targets:
Conditions:
Polymyxin B is a lipopeptide antibiotic isolated from Bacillus polymyxa. Its basic structure consists of a polycationic peptide ring and a tripeptide side chain with a fatty acid tail. Polymyxin B is a mixture of at least four closely related components, polymyxin B1 to B4, with polymyxin B1 and B2 being the two major components. Polymyxin B acts on Gram-negative bacteria by interacting with lipopolysaccharide (LPS) of the outer membrane and destabilizing it. Polymyxin B is indicated for the treatment of many bacterial diseases such as meningeal infections, urinary tract infections and bacteremia.
Status:
US Approved OTC
Source:
21 CFR 333.110(a) first aid antibiotic:ointment bacitracin
Source URL:
First marketed in 1921
Class:
MIXTURE
Targets:
Conditions:
Bacitracin is a polypeptide antibiotic produced by Bacillus subtilis and Bacillus licheniformis. Bacitracin in combination with neomycin and polymyxin B is indicated for the treatment of many bacterial diseases. The antibacterial properties of bacitracin are mediated by its binding to C55-isoprenyl pyrophosphate, resulting in inhibition of cell wall biosynthesis.
Status:
US Approved OTC
Source:
21 CFR 349.12(c) ophthalmic:demulcents gelatin
Source URL:
First marketed in 1921
Class:
MIXTURE
Status:
US Approved OTC
Source:
21 CFR 358.610 pediculicide pyrethrum extract
Source URL:
First marketed in 1921
Class:
MIXTURE
Status:
US Approved OTC
Source:
21 CFR 349.12(a)(3) ophthalmic:demulcents hydroxypropyl methycellulose
Source URL:
First approved in 1999
Source:
Allercaine with Bittran II by Tomlyn Products, a Division of Vetoquinol USA, Inc.
Source URL:
Class:
POLYMER
Status:
US Approved OTC
Source:
21 CFR 349.12(d)(3) ophthalmic:demulcents polyethylene glycol 400
Source URL:
First approved in 1997
Source:
ANDA208851
Source URL:
Class:
POLYMER
Status:
US Approved OTC
Source:
21 CFR 349.12(a)(4) ophthalmic:demulcents methylcellulose
Source URL:
First approved in 1995
Source:
ANDA090666
Source URL:
Class:
POLYMER
Status:
US Approved OTC
Source:
21 CFR 349.12(a)(2) ophthalmic:demulcents hydroxyethylcellulose
Source URL:
First approved in 1990
Source:
M016
Source URL:
Class:
POLYMER
Status:
US Approved OTC
Source:
21 CFR 332.10 antiflatulent simethicone
Source URL:
First approved in 1990
Source:
21 CFR 343
Source URL:
Class:
POLYMER
Status:
US Approved OTC
Source:
21 CFR 349.12(a)(3) ophthalmic:demulcents hypromellose
Source URL:
First approved in 1984
Source:
NDA018716
Source URL:
Class:
POLYMER
